Shanghai Keji Pharmaceutical

CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of hematologic malignancies and solid tumors. The company has established a comprehensive pipeline targeting antigens such as GPC3, Claudin 18.2, and BCMA, with its lead product, zevorcabtagene autoleucel (zevor-cel), recently receiving approval in China for multiple myeloma. CARsgen distinguishes itself through proprietary technology platforms like CycloCAR and LADAR, which aim to enhance the efficacy and safety of CAR-T therapies in solid tumors. Headquartered in Shanghai with operations in the United States, the company is a leader in the global CAR-T landscape, particularly in the development of therapies for gastrointestinal cancers.